<scp>HER2</scp> overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the <scp>QUASAR</scp>, <scp>FOCUS</scp> and <scp>PICCOLO</scp> colorectal cancer trialsSusan D. Richman, Philip Quirke, Morag Taylor et al.|The Journal of Pathology|2015Cited by 238
Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With<i>RAS</i>Wild-Type Advanced Colorectal CancerJenny F. Seligmann, Michel Seymour, Faye Elliott et al.|JAMA Oncology|2016Cited by 115
Clinical and molecular characteristics and treatment outcomes of advanced right-colon, left-colon and rectal cancers: data from 1180 patients in a phase III trial of panitumumab with an extended biomarker panelJenny F. Seligmann, Michel Seymour, Philip Quirke et al.|Annals of Oncology|2020Cited by 18